SOBRE ARTAX BIOPHARMA
Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T-cell activation. Specific control over T-cells through TCR, provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.
Artax Biopharma offices
1 Broadway, Massachusetts Institute of Technology, Cambridge, MA 02142, USA